Based on LUMINOSITY study, U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to Teliso-V for the treatment of patients with advanced/metastatic epidermal growth factor receptor (EGFR) (WT), non-squamous NSCLC with high levels of c-Met-OE whose disease has progressed on or after platinum-based therapy. This evidence concerns the gene MET and non-small cell lung carcinoma.